Built on More Than a Century of Scientific Innovation
We bring together specialized expertise and capabilities shaped by Ajinomoto Group’s more than 100-year legacy of science and innovation.
Specialized CDMO Services Since 2018
Aji Bio-Pharma brings together businesses with deep roots in biopharma development and manufacturing, including the extensive manufacturing heritage of our Wetteren, Belgium site and Ajinomoto-developed technologies such as AJIPHASE™, AJICAP™, and CORYNEX™. This laid the foundation for Aji Bio-Pharma Services, formed in 2018 as a global CDMO.
-
2025
Sold all shares of Ajinomoto Althea to PCI.
-
2023
Aji Bio-Pharma Services acquires Forge Biologics, adding specialized AAV gene therapy development and manufacturing capabilities in the United States.
-
2020
Aji Bio-Pharma Services completes the acquisition of Granules OmniChem Private Limited in India, expanding its global manufacturing network and small molecule capabilities.
-
2019
GeneDesign Inc., a wholly owned Ajinomoto company in Osaka, Japan, joins Aji Bio-Pharma Services, expanding the organization’s oligonucleotide development and manufacturing capabilities.
-
2018
Ajinomoto Althea and OmniChem unite to form Ajinomoto Bio-Pharma Services, bringing together established CDMO capabilities and operations in the United States and Belgium.
